[go: up one dir, main page]

PL1864666T3 - Czynnik ochronny dla komórki neuronalnej siatkówki zawierający jako składnik aktywny pochodną prostaglandyny F2 alfa - Google Patents

Czynnik ochronny dla komórki neuronalnej siatkówki zawierający jako składnik aktywny pochodną prostaglandyny F2 alfa

Info

Publication number
PL1864666T3
PL1864666T3 PL06730774T PL06730774T PL1864666T3 PL 1864666 T3 PL1864666 T3 PL 1864666T3 PL 06730774 T PL06730774 T PL 06730774T PL 06730774 T PL06730774 T PL 06730774T PL 1864666 T3 PL1864666 T3 PL 1864666T3
Authority
PL
Poland
Prior art keywords
active ingredient
protective agent
cell containing
neuronal cell
retinal neuronal
Prior art date
Application number
PL06730774T
Other languages
English (en)
Inventor
Naruhiro Ishida
Atsushi Shimazaki
Original Assignee
Agc Inc
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agc Inc, Santen Pharmaceutical Co Ltd filed Critical Agc Inc
Publication of PL1864666T3 publication Critical patent/PL1864666T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL06730774T 2005-03-31 2006-03-31 Czynnik ochronny dla komórki neuronalnej siatkówki zawierający jako składnik aktywny pochodną prostaglandyny F2 alfa PL1864666T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005100348 2005-03-31
PCT/JP2006/306826 WO2006106915A1 (ja) 2005-03-31 2006-03-31 プロスタグランジンＦ2α誘導体を有効成分として含む網膜神経細胞保護剤
EP06730774A EP1864666B1 (en) 2005-03-31 2006-03-31 Protective agent for retinal neuronal cell containing prostaglandin f2 alpha derivative as active ingredient

Publications (1)

Publication Number Publication Date
PL1864666T3 true PL1864666T3 (pl) 2013-02-28

Family

ID=37073466

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06730774T PL1864666T3 (pl) 2005-03-31 2006-03-31 Czynnik ochronny dla komórki neuronalnej siatkówki zawierający jako składnik aktywny pochodną prostaglandyny F2 alfa

Country Status (14)

Country Link
US (2) US20090234005A1 (pl)
EP (1) EP1864666B1 (pl)
KR (1) KR101396731B1 (pl)
CN (2) CN102293774A (pl)
CA (1) CA2602573C (pl)
CY (1) CY1113473T1 (pl)
DK (1) DK1864666T3 (pl)
ES (1) ES2389500T3 (pl)
NO (1) NO339794B1 (pl)
PL (1) PL1864666T3 (pl)
PT (1) PT1864666E (pl)
RU (1) RU2414904C2 (pl)
SI (1) SI1864666T1 (pl)
WO (1) WO2006106915A1 (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI495471B (zh) * 2003-08-12 2015-08-11 R Tech Ueno Ltd 促進毛髮生長之組成物及方法
US7666912B2 (en) 2006-03-23 2010-02-23 Massachusetts Eye And Ear Infirmary Compositions and methods for reducing body fat
WO2008133021A1 (ja) * 2007-04-12 2008-11-06 R-Tech Ueno, Ltd. プロスタグランジンＦ２α化合物を有効成分として含む視神経障害改善剤組成物
WO2009025763A2 (en) * 2007-08-16 2009-02-26 Schepens Eye Research Institute Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues
CN102143753B (zh) * 2008-09-04 2013-07-03 参天制药株式会社 含有15,15-二氟前列腺素F2α衍生物作为有效成分的毛发生长促进剂
US20120014970A1 (en) * 2009-01-09 2012-01-19 Reza Dana Therapeutic Compositions for Treatment of Corneal Disorders
US10117906B2 (en) 2009-01-09 2018-11-06 The Schepens Eye Research Institute, Inc. Methods for reducing corneal nerves damage, corneal lymphangiogenesis or immunity to corneal antigens in dry-eye associated ocular surface diseases by IL-1Ra
JP5695035B2 (ja) 2009-06-03 2015-04-01 フォーサイト・ビジョン５・インコーポレイテッドＦｏｒｓｉｇｈｔ Ｖｉｓｉｏｎ５，Ｉｎｃ． 前眼部薬物供給
SG187770A1 (en) 2010-08-12 2013-03-28 Univ Nanyang Tech A liposomal formulation for ocular drug delivery
CA2866067C (en) 2011-01-19 2015-04-21 Topokine Therapeutics, Inc. Uses of certain f-series prostaglandin analogs for treating diabetes and dyslipidemia
ES2912370T3 (es) 2011-09-14 2022-05-25 Forsight Vision5 Inc Aparato para inserción ocular
US8426471B1 (en) 2011-12-19 2013-04-23 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
CN104884006B (zh) 2012-10-26 2017-12-15 弗赛特影像5股份有限公司 用于持续释放药物到眼睛的眼科系统
NO2753788T3 (pl) 2013-05-10 2018-06-16
US9820993B2 (en) 2013-05-15 2017-11-21 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
US10188661B2 (en) 2014-06-27 2019-01-29 Topokine Therapeutics, Inc. Topical dosage regimen
WO2016168141A1 (en) 2015-04-13 2016-10-20 Forsight Vision5, Inc. Ocular insert composition of semi-crystalline or crystalline pharmaceutically active agent

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599353A (en) 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
US4822820A (en) * 1986-11-24 1989-04-18 Alcon Laboratories, Inc. Use of tri-methyl PG-F2 a and derivatives in glaucoma therapy
JPH0251225A (ja) 1988-08-15 1990-02-21 Shin Etsu Chem Co Ltd 半導体拡散炉用炉芯管
ATE420857T1 (de) 1988-09-06 2009-01-15 Pfizer Health Ab Prostaglandin-derivate zur behandlung von glaukom und ocularer hypertension
US5352708A (en) 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5510383A (en) 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
TW420611B (en) * 1995-03-10 2001-02-01 R Tech Ueno Ltd Pharmaceutical composition containing prostanoic acid compounds for the treatment of optic nerve disorder
JP3501310B2 (ja) 1995-03-10 2004-03-02 日産ディーゼル工業株式会社 ディーゼルエンジンの燃料噴射管の保持装置
JP3625946B2 (ja) * 1995-03-10 2005-03-02 株式会社アールテック・ウエノ 視神経障害改善剤
ZA9610741B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
DK0857718T3 (da) * 1996-06-10 2002-12-16 Sucampo Ag Endothelinantagonist
JPH1087607A (ja) 1996-09-17 1998-04-07 Asahi Glass Co Ltd 含フッ素プロスタグランジン誘導体の製造方法
JP4004109B2 (ja) * 1996-09-17 2007-11-07 参天製薬株式会社 含フッ素プロスタグランジン誘導体および医薬
WO1998012175A1 (en) 1996-09-17 1998-03-26 Asahi Glass Company Ltd. Fluorinated prostaglandin derivatives and medicines
JPH10259179A (ja) 1996-09-19 1998-09-29 Santen Pharmaceut Co Ltd 多置換アリールオキシ基を有するプロスタグランジン類およびその用途
JP3480549B2 (ja) * 1996-12-26 2003-12-22 参天製薬株式会社 ジフルオロプロスタグランジン誘導体およびその用途
US5877211A (en) * 1997-11-21 1999-03-02 Allergan EP2 receptor agonists as neuroprotective agents for the eye
US6225348B1 (en) * 1998-08-20 2001-05-01 Alfred W. Paulsen Method of treating macular degeneration with a prostaglandin derivative
KR20010083884A (ko) * 1998-10-13 2001-09-03 세파론, 인코포레이티드 눈 질환 치료제
JP4372905B2 (ja) 1999-09-02 2009-11-25 興和株式会社 網膜神経細胞保護剤
AU2001228863A1 (en) 2000-01-31 2001-08-14 Santen Pharmaceutical Co. Ltd. Remedies for ophthalmic diseases
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
ATE428429T1 (de) * 2000-03-24 2009-05-15 Sucampo Ag Prostaglandine zur behandlung von lichtstrahlung erzeugten augenerkrankungen wie photoretinitis
AU2001286210A1 (en) 2000-09-13 2002-03-26 Asahi Glass Company, Limited Eye drops
JP2002293771A (ja) 2001-03-30 2002-10-09 Asahi Glass Co Ltd 新規なエーテル型ジフルオロプロスタグランジン誘導体またはその塩
CN101310771B (zh) 2001-04-11 2012-08-08 千寿制药株式会社 视觉功能障碍改善剂
WO2002100833A1 (en) 2001-06-12 2002-12-19 Sumitomo Pharmaceuticals Company, Limited Rho KINASE INHIBITORS
CA2454544A1 (en) 2001-07-02 2003-01-16 Santen Pharmaceutical Co., Ltd. Optic nerve protecting agents containing .alpha.1 receptor blocker as active ingredient
JP2003146904A (ja) 2001-11-08 2003-05-21 Nippon Shinyaku Co Ltd 緑内障治療薬
JP2003321442A (ja) * 2002-04-24 2003-11-11 Santen Pharmaceut Co Ltd 新規なジフルオロプロスタグランジンアミド誘導体
WO2005035506A1 (ja) 2003-10-15 2005-04-21 Ube Industries, Ltd. 新規インダゾール誘導体

Also Published As

Publication number Publication date
CN101151034B (zh) 2012-06-06
RU2007140309A (ru) 2009-05-10
CA2602573C (en) 2013-10-08
CY1113473T1 (el) 2016-06-22
US20120010288A1 (en) 2012-01-12
EP1864666A1 (en) 2007-12-12
NO339794B1 (no) 2017-01-30
KR20070116632A (ko) 2007-12-10
SI1864666T1 (sl) 2012-10-30
EP1864666A4 (en) 2008-04-02
NO20075464L (no) 2007-12-18
CN102293774A (zh) 2011-12-28
ES2389500T3 (es) 2012-10-26
US9138438B2 (en) 2015-09-22
EP1864666B1 (en) 2012-08-15
KR101396731B1 (ko) 2014-05-19
CA2602573A1 (en) 2006-10-12
PT1864666E (pt) 2012-09-06
RU2414904C2 (ru) 2011-03-27
US20090234005A1 (en) 2009-09-17
CN101151034A (zh) 2008-03-26
DK1864666T3 (da) 2012-10-29
WO2006106915A1 (ja) 2006-10-12

Similar Documents

Publication Publication Date Title
PL1864666T3 (pl) Czynnik ochronny dla komórki neuronalnej siatkówki zawierający jako składnik aktywny pochodną prostaglandyny F2 alfa
IL184695A0 (en) Gastroresistant pharmaceutical formulations containing rifaximin
AP2441A (en) Low-faoming aqueous formulations used for crop protection
IL201418A0 (en) Therapeutic agent for glaucoma containing adenosine derivative as active ingredient
IL191907A0 (en) Azepinoindole derivatives as pharmaceutical agents
ZA200807767B (en) Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
ZA200706622B (en) Microimplants for ocular administration
IL185479A0 (en) Dipeptidyl peptidase-iv inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent
IL190174A0 (en) Topical film-forming monophasic formulations
SI1864665T1 (sl) Imunosupresivno sredstvo, ki obsega heterociklično spojino kot učinkovino
ZA200709094B (en) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivatives as medicaments for the treatment of infertility
ZA200709090B (en) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivatives as medicaments for the treatment of infertility
PL1932522T3 (pl) Środek terapeutyczny do leczenia choroby wątroby zawierający jako składnik czynny pochodną 2-amino-1,3-propanodiolu
IL186831A0 (en) 4-phenyl- 5-oxo - 1,4,5,6,7,8 - hexahydroquinoline derivatives as medicaments for the treatment of infertility
ZA200900207B (en) Aminoalcohol derivative and immunosuppressant containing the same as active ingredient
IL188831A0 (en) Compositions for reducing the incidence of drug induced arrhythmia
EP1858522A4 (en) PHARMACEUTICALLY ACCEPTABLE CARRIER FOR OPHTHALMIC COMPOSITIONS
PL1905453T3 (pl) Kompozycja konserwująca do zastosowania okulistycznego
EP1884237A4 (en) NEUROCYTE PROTECTIVE AGENT COMPRISING AN AMIDINO DERIVATIVE AS AN ACTIVE SUBSTANCE
EP1884236A4 (en) ANGIOGENESIS INHIBITOR CONTAINING AN AMINATED DERIVATIVE AS AN ACTIVE SUBSTANCE
IL184527A0 (en) Tetrahydrofurane derivatives for use as inhibitors of matrix metalloproteinases
ZA200803615B (en) Agent for protecting body cells
KR100673974B9 (ko) 2,2-디메틸-3-알킬에테르-4-알콕시-6-알킬 아미노벤조피란 유도체를 유효성분으로 함유하는 pge2 활성에 관련된 염증질환 치료제
EP2016945A4 (en) A THIAZONE DERIVATIVE PHARMACEUTICAL ACTIVE SUBSTANCE
EP1872783A4 (en) THERAPEUTIC AGENT FOR CORNEAL / CONJUNCTIVAL DISORDER